PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2148947-4	1990	PAF activity was assessed in bioassay and expressed relative to the activity of known amounts of authentic PAF, 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	164-169	PCNA clamp associated factor	Homo sapiens	0-3
2555201-1	1989	Platelet-activating factor (PAF) (1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) produced dose-dependent depletion of the goblet cell population associated with the conjunctival epithelium.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	34-88	PCNA clamp associated factor	Homo sapiens	0-26
35202001-16	2022	C16-PAF reversed the effects of miR-223-3p mimics on inflammation and ERK1/2 signaling pathway.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	0-7	mitogen-activated protein kinase 3	Homo sapiens	70-76
2555201-1	1989	Platelet-activating factor (PAF) (1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) produced dose-dependent depletion of the goblet cell population associated with the conjunctival epithelium.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	34-88	PCNA clamp associated factor	Homo sapiens	28-31
7116669-1	1982	Injections of 1-)-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (alkylacetyl-GPC, 0.2-5.0 nmol/300 g body weight) induced dose-related hypotension and tachycardia in spontaneous hypertensive (SHR) and normotensive control (WKY) rats.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	14-64	glycophorin C	Rattus norvegicus	78-81
6425292-5	1984	The presence of PAF in eosinophils was established by demonstrating the lipid nature of the compound, the RF value being identical with that of synthetic 1-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on thin layer chromatograms, and by its ability to induce serotonin release from rabbit platelets.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	154-202	PCNA clamp associated factor	Homo sapiens	16-19
3087218-6	1986	The major species of the PAF material produced by mesangial cells was identified as 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine after HPLC separation, followed by fast atom bombardment and gas chromatography-mass spectrometry.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	84-134	PCNA clamp associated factor	Rattus norvegicus	25-28
30970255-5	2019	Mice lacking the receptor of the lipid mediator platelet-activating factor (PAF; 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) showed reduced production of IL-10 and IL-23 that is explained by the requirement of acetyl-CoA for PAF biosynthesis and its ensuing autocrine function.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	81-131	interleukin 10	Mus musculus	162-167
6872358-1	1983	1-O-Hexadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (C16-AGEPC) and 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (C18-AGEPC) stimulated a time- and concentration-dependent release of granule-associated lysozyme and beta-glucuronidase from human neutrophils.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	0-56	glucuronidase beta	Homo sapiens	232-250
30970255-5	2019	Mice lacking the receptor of the lipid mediator platelet-activating factor (PAF; 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) showed reduced production of IL-10 and IL-23 that is explained by the requirement of acetyl-CoA for PAF biosynthesis and its ensuing autocrine function.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	81-131	interleukin 23, alpha subunit p19	Mus musculus	172-177
29550277-5	2018	Lp-PLA2 hydrolyzes 1-O-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16 PAF) to 1-O-Hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine (LysoPAF).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	19-69	phospholipase A2 group VII	Homo sapiens	0-7
15845398-2	2005	Endothelial-derived hyperpolarizing factor (EDHF) functions as a potent vasodilator to regulate vascular tone, and its production is regulated by soluble epoxide hydrolase (sEH).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	36-42	epoxide hydrolase 2	Homo sapiens	146-171
28154204-4	2017	The structures of the N-acyl chain and long-chain base (LCB) of the molecule were determined by MS4 on [M + H - H2O - (1-O-FA)]+ ions that yielded multiple sets of specific ions.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	119-122	clathrin, light polypeptide (Lcb)	Mus musculus	56-59
22958411-5	2012	The structure-activity relationships indicated that (i) the 1-O-(methylthio)methyl substituent in lycorine was better than the 1-O-acetyl group for the inhibition of cholinesterase; (ii) the acylated or etherified derivatives of lycorine and lycorin-2-one were more potent against hBChE than hAChE; and (iii) the oxidation of lycorine at C-2 decreases the activity.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	127-130	butyrylcholinesterase	Homo sapiens	166-180
21980127-2	2011	A major component of EDRF activity derives from hyperpolarization and is termed endothelium-derived hyperpolarizing factor (EDHF).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	116-122	alpha hemoglobin stabilizing protein	Mus musculus	21-25
25280113-2	2014	The V-O BDE in 1-O is 6.3 +- 3.2 kcal mol(-1) lower than the previously reported value for 2-O and the V-S BDE in 1-S is 3.3 +- 3.1 kcal mol(-1) lower than that in 2-S.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	15-18	homeobox D13	Homo sapiens	8-11
25280113-2	2014	The V-O BDE in 1-O is 6.3 +- 3.2 kcal mol(-1) lower than the previously reported value for 2-O and the V-S BDE in 1-S is 3.3 +- 3.1 kcal mol(-1) lower than that in 2-S.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	15-18	homeobox D13	Homo sapiens	107-110
22958411-5	2012	The structure-activity relationships indicated that (i) the 1-O-(methylthio)methyl substituent in lycorine was better than the 1-O-acetyl group for the inhibition of cholinesterase; (ii) the acylated or etherified derivatives of lycorine and lycorin-2-one were more potent against hBChE than hAChE; and (iii) the oxidation of lycorine at C-2 decreases the activity.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	60-63	butyrylcholinesterase	Homo sapiens	166-180
22958411-5	2012	The structure-activity relationships indicated that (i) the 1-O-(methylthio)methyl substituent in lycorine was better than the 1-O-acetyl group for the inhibition of cholinesterase; (ii) the acylated or etherified derivatives of lycorine and lycorin-2-one were more potent against hBChE than hAChE; and (iii) the oxidation of lycorine at C-2 decreases the activity.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	60-63	butyrylcholinesterase	Homo sapiens	281-286
22958411-5	2012	The structure-activity relationships indicated that (i) the 1-O-(methylthio)methyl substituent in lycorine was better than the 1-O-acetyl group for the inhibition of cholinesterase; (ii) the acylated or etherified derivatives of lycorine and lycorin-2-one were more potent against hBChE than hAChE; and (iii) the oxidation of lycorine at C-2 decreases the activity.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	60-63	acetylcholinesterase (Cartwright blood group)	Homo sapiens	292-297
22958411-5	2012	The structure-activity relationships indicated that (i) the 1-O-(methylthio)methyl substituent in lycorine was better than the 1-O-acetyl group for the inhibition of cholinesterase; (ii) the acylated or etherified derivatives of lycorine and lycorin-2-one were more potent against hBChE than hAChE; and (iii) the oxidation of lycorine at C-2 decreases the activity.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	60-63	complement C2	Homo sapiens	338-341
20008037-4	2010	Reaction phenotyping for the glucuronidation of CP with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	160-163	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	81-84
20008037-4	2010	Reaction phenotyping for the glucuronidation of CP with 12 expressed human liver UGT isoforms has identified UGT2B7 as having the highest activity for 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	160-163	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	109-115
20008037-9	2010	These results suggest that UGT2B7 is the primary human hepatic UDP-glucuronosyltransferase isoform catalyzing 3-O- and 1-O-CP glucuronidation with minor contributions from UGT1A6 and UGT1A9.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	119-122	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	27-33
19717402-1	2010	AIMS: A CYP2C9-dependent endothelium-derived hyperpolarizing factor (EDHF) controls blood flow in many microvascular beds of various species by targeting vascular smooth muscle potassium channels.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	61-67	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	8-14
19827129-3	2009	Owing to its important physiological role, we wanted to characterize membrane intercalation and interaction of PAF-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) by studying its capacity to induce during short-term incubations at high concentrations cell shape alterations, phosphatidylserine exposure, and hemolysis in human erythrocytes.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	119-169	PCNA clamp associated factor	Homo sapiens	111-114
19071607-2	2007	The (1)O(2) produced in the reaction was further characterized and confirmed by (i) chemical trapping of (1)O(2) with 9,10-diphenylanthracene (DPA), the corresponding endoperoxide was detected by HPLC and (ii) spin trapping of (1)O(2) with 2,2,6,6-tetramethyl-4-piperidinol (TMP-OH), the corresponding free radical of TMP-OH oxide (TMPO) was detected by electron spin resonance (ESR) spectroscopy.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	4-8	thymopoietin	Homo sapiens	332-336
17258180-11	2007	ACh caused dilation via endothelial-derived relaxing factor (EDRF) in WT mice and via endothelial-derived hyperpolarizing factor (EDHF) in eNOS(-/-) mice.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	53-59	alpha hemoglobin stabilizing protein	Mus musculus	61-65
16713366-1	2006	OBJECTIVE: The major aim of this study was to determine whether the angiotensin converting enzyme (ACE) inhibitors, captopril or enalapril, restore the diminished vasodilator potency of the endothelium-dependent agonist, acetylcholine (ACh), and the endothelium-derived relaxing factor (EDRF), L-S-nitrosocysteine (L-SNC), in conscious Spontaneously Hypertensive (SH) rats.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	279-285	angiotensin I converting enzyme	Rattus norvegicus	68-97
16713366-1	2006	OBJECTIVE: The major aim of this study was to determine whether the angiotensin converting enzyme (ACE) inhibitors, captopril or enalapril, restore the diminished vasodilator potency of the endothelium-dependent agonist, acetylcholine (ACh), and the endothelium-derived relaxing factor (EDRF), L-S-nitrosocysteine (L-SNC), in conscious Spontaneously Hypertensive (SH) rats.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	279-285	angiotensin I converting enzyme	Rattus norvegicus	99-102
15845398-2	2005	Endothelial-derived hyperpolarizing factor (EDHF) functions as a potent vasodilator to regulate vascular tone, and its production is regulated by soluble epoxide hydrolase (sEH).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	36-42	epoxide hydrolase 2	Homo sapiens	173-176
15026031-5	2004	In many vessels, endothelium-derived hyperpolarizing factor (EDHF) seems identical to the K(+) derived from endothelial cells; it activates Na(+)/K(+)-ATPases (particularly those containing alpha2 and alpha3 subunits) and inward rectifiers (particularly Kir2.1) located on the vascular myocytes.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	53-59	potassium inwardly rectifying channel subfamily J member 2	Homo sapiens	254-260
10226361-0	1999	Negative ion electrospray and tandem mass spectrometric analysis of platelet activating factor (PAF) (1-hexadecyl-2-acetyl-glycerophosphocholine).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	102-144	PCNA clamp associated factor	Homo sapiens	68-94
10868946-3	2000	In particular, leptin-evoked vasorelaxation is impaired by nitric oxide synthase inhibition in aorta (delta% of maximal response: from 36 +/- 3 to 3 +/- 1, P < 0.01) and by endothelium-derived hyperpolarizing factor (EDHF) inhibition in mesenteric arteries (delta% of maximal response: from 30 +/- 5 to 7 +/- 2, P < 0.01), suggesting that vasorelaxation evoked by leptin is heterogeneous and related to the vascular bed.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	212-218	leptin	Rattus norvegicus	15-21
12452715-1	2002	The ene reaction of singlet oxygen ((1)O(2)), triazolinedione (TAD), and nitrosoarene, specifically 4-nitronitrosobenzene (ArNO), with the tetrasubstituted 1,3-allylically strained, chiral allylic alcohol 3,4-dimethylpent-3-en-2-ol (2) leads to the threo-configured ene products in high diastereoselectivity, a consequence of the hydroxy-group directivity.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	36-40	cytohesin 2	Homo sapiens	123-127
10226361-0	1999	Negative ion electrospray and tandem mass spectrometric analysis of platelet activating factor (PAF) (1-hexadecyl-2-acetyl-glycerophosphocholine).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	102-144	PCNA clamp associated factor	Homo sapiens	96-99
10226361-1	1999	The analysis of 1-hexadecyl-2-acetyl-glycerophosphocholine (platelet activating factor, PAF) by negative ion and normal-phase liquid chromatography/tandem mass spectrometry (LC/MS/MS) was investigated as an alternative technique to the currently used gas chromatography/MS and positive ion LC/MS/MS procedures.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	16-58	PCNA clamp associated factor	Homo sapiens	60-86
7535766-5	1995	Bradykinin initiated a transient increase in cytosolic Ca2+ concentration in both control and 1-O-HDG supplemented cells, indicating that the initial receptor linked events were not affected by 1-O-HDG supplementation.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	94-97	kininogen 1	Homo sapiens	0-10
7488633-6	1995	The predominant PAF was 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine or 16:0-alkyl-PAF (0.75 +/- 0.09 pmol/ml saliva; mean +/- S.E.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	24-74	PCNA clamp associated factor	Homo sapiens	16-19
8423671-3	1993	PAF activity was assessed in platelet bioassay and expressed relative to the activity of authentic PAF, 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16:0-AGEPC).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	104-154	PCNA clamp associated factor	Homo sapiens	99-102
7907280-1	1994	Platelet-activating factor (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine [PAF]) is a potent lipid autocoid produced by many cell types.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	28-78	PCNA clamp associated factor	Homo sapiens	80-83
7562354-4	1995	PAF activity was determined in bioassay relative to authentic PAF (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine; 16:0-alkyl-PAF).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	67-117	PCNA clamp associated factor	Homo sapiens	0-3
7929136-3	1994	Activation by phenylalanine and reduction by the co-factor (6R)-tetrahydrobiopterin (BH4) are required for formation of active liver phenylalanine hydroxylase.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	52-58	phenylalanine hydroxylase	Rattus norvegicus	133-158
8400088-4	1993	PAF bioactive material extracted and purified from the plasma of patients was shown to be chemically and biologically identical to the synthetic C-16 PAF (1-O-hexadecyl-2-acetyl-sn-glyceryl 3-phosphorylcholine).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	155-209	PCNA clamp associated factor	Homo sapiens	0-3
8400088-4	1993	PAF bioactive material extracted and purified from the plasma of patients was shown to be chemically and biologically identical to the synthetic C-16 PAF (1-O-hexadecyl-2-acetyl-sn-glyceryl 3-phosphorylcholine).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	155-209	PCNA clamp associated factor	Homo sapiens	150-153
1634507-4	1992	By thin layer chromatography and reverse-phase high pressure liquid chromatography, we demonstrated that PAF synthesized by human PMN stimulated with IL-8 is heterogeneous: the 2-acetylated phospholipids having the biological and physicochemical characteristics of PAF include the 1-O-alkyl form, which is produced in large extent (51%), and the 1-acyl form (20%).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	281-284	PCNA clamp associated factor	Homo sapiens	105-108
1634507-4	1992	By thin layer chromatography and reverse-phase high pressure liquid chromatography, we demonstrated that PAF synthesized by human PMN stimulated with IL-8 is heterogeneous: the 2-acetylated phospholipids having the biological and physicochemical characteristics of PAF include the 1-O-alkyl form, which is produced in large extent (51%), and the 1-acyl form (20%).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	281-284	C-X-C motif chemokine ligand 8	Homo sapiens	150-154
1819719-5	1991	The PAF detected was equivalent to 1-1.4 pmol of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine, three quarters of which were recovered in cell-associated form.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	49-99	PCNA clamp associated factor	Homo sapiens	4-7
1511005-0	1992	Albumin and fatty acid effects on the stimulated production of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) by human polymorphonuclear leukocytes.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	63-113	PCNA clamp associated factor	Homo sapiens	115-118